To include your compound in the COVID-19 Resource Center, submit it here.

TaiMed's ibalizumab gets FDA Priority Review for HIV

TaiMed Biologics Inc. (TPEx:4147) said FDA accepted and granted Priority Review to a BLA for ibalizumab

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE